ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO445

Effects of Nonsteroidal Mineralocorticoid Antagonist (Finerenone) in Western Diet-Induced Kidney Diseases

Session Information

Category: Diabetic Kidney Disease

  • 701 Diabetic Kidney Disease: Basic

Authors

  • Myakala, Komuraiah, Georgetown University Medical Center, Washington, District of Columbia, United States
  • Shults, Nataliia V., Georgetown University Medical Center, Washington, District of Columbia, United States
  • Wang, Xiaoxin, Georgetown University Medical Center, Washington, District of Columbia, United States
  • Korolowicz, Kyle E., Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
  • Rodriguez, Olga C., Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
  • Albanese, Chris, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
  • Levi, Moshe, Georgetown University Medical Center, Washington, District of Columbia, United States
Background

Mineralocorticoid receptor (MR) overactivation plays a crucial role in the pathogenesis of chronic kidney disease, several cardiovascular and arterial diseases. Recently the non-steroidal MR antagonist Finerenone (FN) was shown to have highly beneficial cardiac and renal protective effects. The purpose of these studies was to determine the mechanisms of the beneficial effects FN in kidney disease in a mouse model of western diet induced obesity and insulin resistance.

Methods

2-month old C57BL/6J mice fed on low fat (LF) or western diet (WD) were treated with vehicle or FN for 6-months (prevention studies) or after 3 months on the LF or WD at 5 months of age, mice treated with vehicle or FN for 3 months (intervention studies) until they were 8 months old.

Results

Mice fed a Western diet (WD) had increased body weight and kidney weight, whereas Finerenone reduced kidney weight ratio without affecting body weight and blood glucose levels remained unchanged. WD-fed mice had higher plasma levels of TG and TC, reduced by FN. The WD fed mice exhibited significantly increased albuminuria and KIM1 which was decreased with FN. Kidneys of WD-fed mice showed increased expression levels of pro-inflammatory cytokines (MCP1, TGFβ), innate immunity pathways (TLR2, STING, STAT3), and fibrosis marker fibronectin and PAI-1, which were significantly reduced by FN. Interestingly, kidney cholesterol and ceramide levels were markedly increased in WD fed mice, which were reduced by FN. Electron microscopy revealed glomerular basement membrane disruption, podocyte foot process loss, and mitochondrial structural abnormalities in WD-fed mice, all improved by FN.

Conclusion

Our data shows that administration of Finerenone exhibits a renal protective role and prevents the progression of kidney disease in a mouse model of western diet induced obesity and insulin resistance.

Funding

  • Commercial Support – Bayer